 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2026, vol. 32, issue3
Subject Area: Medicine
-
DOI: 10.5272/jimab.2026323.7124
Published online: 30 September 2026
Case report
J of IMAB. 2026 Jul-Sep;32(3):7124-7126
MOYAMOYA DISEASE - CLINICAL PROGRESSION AND LONG-TERM OUTCOME: A CASE REPORT
Plamen G. Stoev
, Yoanna V. Todorova,
Department of Neurology, University Hospital, Medical University, Pleven, Bulgaria.
ABSTRACT:
Moyamoya disease (MMD) is a chronic cerebrovascular disease, characterized by stenotic- obstructive changes at the terminal portions of the internal carotid artery (ICA) and formation of an abnormal vascular network at the cerebral base. The clinical presentation of MMD may vary from TIA and ischemic or hemorrhagic strokes to seizures, headaches and cognitive impairment. Typically strokes in the MCA and ACA are prevalent at the initial stages, while PCA vascular incidents increase with disease progression and are considered to be a poor prognostic factor.
We present a case of a 21-year-old man admitted at the Neurology Department with Jacksonian seizures in the right arm followed by right-sided weakness and sensory-motor aphasia. Over the following decades he suffered subsequent transitory episodes of visual impairment, one ischemic stroke with right-sided weakness and a left thalamic hemorrhage. CT scans, angiographies and MRI showed multiple ischemic lesions. A catheter-based DCA showed multiple stenotic regions in the ICA, MCA and ACA and occlusion of the left PCA in P1 and well-developed collateral network of the right PCA thus confirming the diagnosis of MMD.
Moyamoya should always be considered as a possible cause for vascular events in young adults and especially in children. Therapeutic measures are focused on secondary prophylaxis of ischemic events with antiplatelets as there is no specific treatment available to stop the progression of the disease. Current guidelines suggest surgical methods as the only effective prevention of further disabling ischemic and hemorrhagic strokes.
Keywords: moyamoya disease, ischemic stroke, hemorrhagic stroke,
- Download FULL TEXT /PDF 795 KB/
Please cite this article as: Stoev PG, Todorova YV. Moyamoya disease - clinical progression and long-term outcome: a case report. J of IMAB. 2026 Jul-Sep;32(3):7124-7126. [Crossref - 10.5272/jimab.2026323.7124]
Correspondence to: Dr Plamen Georgiev Stoev, Neurology Clinic, UMHAT Dr Georgi Stranski, Pleven; 8a, Georgi Kochev Str., Pleven 5800, Bulgaria. E-mail: plamen068@gmail.com
REFERENCES:
1. Kim JS. Moyamoya Disease: Epidemiology, Clinical Features, and Diagnosis. J Stroke. 2016 Jan;18(1):2-11. [PubMed]
2. Kappel AD, Feroze AH, Torio E, Sukumaran M, Du R. Management of moyamoya disease: a review of current and future therapeutic strategies. J Neurosurg. 2024 Apr 19;141(4):975-982. [PubMed]
3. Chiu D, Shedden P, Bratina P, Grotta JC. Clinical features of moyamoya disease in the United States. Stroke. 1998 Jul;29(7):1347-51. [PubMed]
4. Zhang X, Xiao W, Zhang Q, Xia D, Gao P, Su J. et al. Progression in moyamoya disease: clinical features, neuroimaging evaluation, and treatment. Current Neuropharmacology. 2022 Feb 1;20(2):292-308. [PubMed]
5. Berry JA, Cortez V, Toor H, Saini H, Siddiqi J. Moyamoya: An Update and Review. Cureus. 2020 Oct 16;12(10):e10994. [PubMed]
6. Ihara M, Yamamoto Y, Hattori Y, Liu W, Kobayashi H, Ishiyama H, et al. Moyamoya disease: diagnosis and interventions. Lancet Neurol. 2022 Aug;21(8):747-758. [PubMed]
7. Gonzalez NR, Amin-Hanjani S, Bang OY, Coffey C, Du R, Fierstra J, et al. Adult Moyamoya Disease and Syndrome: Current Perspectives and Future Directions: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2023 Oct;54(10):e465-e479. [PubMed]
8. Demartini Z Jr, Teixeira BC, Koppe GL, Gatto LAM, Roman A, Munhoz RP. Moyamoya disease and syndrome: a review. Radiol Bras. 2022 Jan-Feb;55(1):31-37. [PubMed]
9. Khan NT, Islam S, Bari A. A Case Report of Moyamoya Disease Presenting as Recurrent Right-Sided Weakness. Cureus. 2023 May 19;15(5):e39209. [PubMed]
10. Nah HW, Kwon SU, Kang DW, Ahn JS, Kwun BD, Kim JS. Moyamoya disease-related versus primary intracerebral hemorrhage: [corrected] location and outcomes are different. Stroke. 2012 Jul;43(7):1947-50. [PubMed]
11. Tatit RT, Rios-Zermeno J, Ghaith AK, Iyer HG, Tawk RG. Association between pre-operative long-term aspirin use and post-operative outcomes following extracranial-intracranial bypass for moyamoya disease: National Inpatient Sample analysis. Clin Neurol Neurosurg. 2026 Aug;267:109443. [PubMed]
Received: 26 February 2026
Published online: 30 September 2026